Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 9/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 9/20 | 0.42 |
| ▸ | VCP | P55072 | 4/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27855513 | 1.00 | KLK1 (0.46) | KLK1DRD2HTR2AHRH1CHRM1 | |
| SCHEMBL12584712 | 0.92 | KLK1 (0.45) | KLK1DRD2HTR2AHRH1CHRM1 | |
| SCHEMBL985985 | 0.88 | KLK1 (0.43) | KLK1DRD2HTR2AHRH1CHRM1 | |
| SCHEMBL12585687 | 0.88 | KLK1 (0.50) | KLK1DRD2HTR2AHRH1CHRM1 | |
| SCHEMBL988224 | 0.88 | DRD2 (0.44) | KLK1DRD2HTR2AHRH1KLKB1 | |
| SCHEMBL989410 | 0.86 | DRD2 (0.45) | KLK1DRD2HTR2AHRH1KLKB1 | |
| SCHEMBL12585769 | 0.85 | VCP (0.43) | CHRM1VCPUSP30 | |
| SCHEMBL987467 | 0.84 | ACACB (0.40) | DRD2CHRM1VCP | |
| SCHEMBL12585664 | 0.84 | ACACB (0.40) | DRD2CHRM1VCP | |
| SCHEMBL988293 | 0.84 | VCP (0.40) | DRD2CHRM1VCPUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | claimed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | claimed |
| CN-102026961-A | Amide compound | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | claimed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | claimed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| CN-102026961-A | Amide compound | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | KLK1 1672/4885DRD2 954/4885HTR2A 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.